-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
WCLC 2020 Archive
-
Study Identifies Lung Cancer Areas of Improvement Across Asia-Pacific Region
Lung cancer prevention and treatment remains a challenge across the Asia-Pacific region, and each country has areas where they could improve, according to a study presented during the Day 2 mini oral session, “MA04: Health Policy and the Real World.” Lung cancer is the leading cause of cancer mortality in the Asia-Pacific region accounting for…
-
Several Studies Assess the Fallout From the COVID-19 Pandemic in Patients With Lung Cancer
The COVID-19 pandemic has undoubtedly altered patient care as countries have locked down to prevent spread of the virus and shifted resources to accommodate surging caseloads. It has also taken a considerable emotional toll on vulnerable individuals, particularly patients with cancer, given fears about contracting the virus and concerns about disruptions in care. Several researchers…
-
Redefining Good Quality Resections in NSCLC
Curative-intent resections for NSCLC often fail. Approximately 20% to 40% of patients with lung cancer who undergo curative-intent resection, experience a relapse, and die within 4 years. One key factor is the quality of the surgery, although there are no universal benchmarks of good quality resection, according to Raymond U. Osarogiagbon, MD, of the Thoracic…
-
Examining Value and Access in Lung Cancer Care, From Screening to Treatment
Appropriate and swift diagnosis and treatment are crucial for patients with lung cancer but can be elusive for many due to cost, healthcare disparities, and other barriers. Factors such as age, gender, and ethnicity can affect not only access to screening and care but also disease outcomes, as can the economic resources and quality of…
-
IASLC Award Recognizes Importance of Cancer Care Teamwork
The IASLC awarded four cancer care teams from around the globe with one of the association’s most prestigious award—the IASLC Cancer Care Team Award (CCTA). The winning teams were announced during the IASLC 2020 World Conference on Lung Cancer Singapore. The CCTA recognizes a single institution in North America, Europe, Latin America, and Asia/Rest of…
-
More Options Needed After First-Line Chemoimmunotherapy in Lung Cancer
As an increasing number of immunotherapy treatments find their way into the front-line treatment of solid tumors, including lung cancer, clinicians are often faced with a lack of options when choosing systemic therapies after chemoimmunotherapy. During the Education Session, “Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC” three speakers provided updates on the current second-line options…
-
Immunohistochemistry’s Important Role in Diagnosis of Thoracic Cancers Explained in a New Atlas
The latest in the series of diagnostic Atlases has been published by the IASLC and its Pathology Committee. Following the highly successful editions on ALK, EGFR, ROS1 and PD-L1, this latest Atlas takes a comprehensive look at diagnostic immunohistochemistry (IHC) and its role in thoracic pathology. The editorial team of Drs. Yasushi Yatabe, Alain Borczuk,…
-
Program Trains Patient Research Advocates to be STARS
What does it take to become a star in any setting? Passion, knowledge, and drive. When it comes to understanding the science of lung cancer, sometimes the experts are the patients themselves. The IASLC is looking for patients and caregivers who want to learn about lung cancer science and research, as well as develop their…
-
Enhancing Your WCLC Experience with Twitter
Even those who are unfamiliar with social media platforms can find Twitter to be an easy way to discuss research and collaborate with colleagues. If you do not already have a Twitter account, you should consider setting one up now! During a virtual conference, Twitter is the best possible replacement for the hallway conversations that…
-
IASLC President Discusses Accomplishments, Adjustments, and The Year Ahead
Dr. Tetsuya Mitsudomi joined the Board of Directors of IASLC in 2011 and has served as its board president since 2019. IASLC awarded Dr. Mitsudomi its Mary J. Matthews Pathology/Translational Research Award in 2013 for a lifetime achievement in pathology and translational research of thoracic malignancies. Dr. Mitsudomi, professor in the Division of Thoracic Surgery…